Test Price
2,800 AED✅ Home Collection Available
PLEC Gene Muscular Dystrophy, Limb‑Girdle, Type 2Q Genetic Test in the UAE | 2800 AED | 2026 DHA Guidelines
تحليل جين PLEC للضمور العضلي الحزامي النوع 2Q في الإمارات | 2800 درهم | معتمد من هيئة الصحة بدبي
Executive Summary & Clinical Promise
- 99.9% Diagnostic Sensitivity – ISO 9001:2015 certified NGS workflow with dual‑pathogenomic validation.
- Premium Home Collection: ISO‑certified cold‑chain transport (8 AM–11 PM) with a dedicated VIP mobile phlebotomist.
- Post‑Test Clinical Guidance: Complimentary tele‑consultation with DHA‑licensed neurologist for result interpretation.
- Direct Insurance Billing Verification via WhatsApp +971 54 548 8731
الملخص التنفيذي: دقة تشخيصية بنسبة 99.9%، خدمة سحب منزلي فاخرة مع سلسلة تبريد معتمدة، وإرشاد إكلينيكي هاتفي بعد الفحص، والتحقق المباشر من تغطية التأمين عبر الواتساب.
Methodology: Next‑Generation Sequencing (NGS) – comprehensive coverage of all coding exons and splice‑site regions of the PLEC gene. Turnaround time: 3–4 weeks. Sample: Blood in EDTA, or extracted DNA, or one drop of blood on an FTA card.
Pre‑test requirement: A detailed clinical history and, where possible, a genetic counselling session to construct a family pedigree for limb‑girdle muscular dystrophy type 2Q.
Comprehensive NGS Test Overview
PLEC‑related limb‑girdle muscular dystrophy type 2Q (LGMD2Q) is an autosomal recessive myopathy caused by biallelic mutations in the plectin gene. Our NGS test delivers definitive molecular diagnosis for affected individuals, carrier screening for at‑risk family members, and prognostic insight. For Arabic‑speaking patients, يقدم فحص جين PLEC تشخيصًا جزيئيًا دقيقًا لحالة الضمور العضلي الحزامي.
| Feature | Our Test (UAE Center) | Closest Alternative |
|---|---|---|
| Methodology | Full‑gene NGS with CNV analysis | Single‑gene Sanger sequencing (limited) |
| Turnaround | 3–4 weeks | 6–8 weeks |
| Home Collection | 8 AM–11 PM, ISO cold chain | Clinic visit only |
Physician Insight & Safety Protocol
“As a DHA‑licensed Consultant Neurologist, I urge patients and families to view this genetic test as a map, not a sentence. A positive PLEC mutation confirms the cause of weakness, but clinical correlation with EMG, creatinine kinase, and muscle biopsy is still essential. We walk this journey with you – from initial counselling through post‑test interpretation – always prioritizing emotional support and precise medical planning.”
— Dr. PRABHAKAR REDDY, DHA License No. 61713011
⚠ Medication Safety: Do not discontinue any prescribed medication (e.g., corticosteroids, immunosuppressants, or cardiac drugs) before or after the test without direct consultation with your treating physician.
Exclusion Criteria & Emergency Red Flags
- Exclusion: Inability to provide informed consent (minors require a legal guardian). Active bleeding disorder or therapeutic anticoagulation not optimized for phlebotomy.
- Red Flags — Seek Emergency Care if: You develop expanding hematoma, uncontrolled bleeding, fainting, or signs of infection (fever, redness, pus) at the blood draw site after home collection.
- Genetic results that reveal incidental findings of life‑threatening significance will be communicated urgently by a specialist via phone, with an automatic appointment for a follow‑up clinic consultation.
Patient FAQ & Clinical Guidance
1. What is the PLEC gene and how does it cause limb‑girdle muscular dystrophy type 2Q?
The PLEC gene encodes plectin, a cytoskeletal linker protein critical for muscle fibre integrity – biallelic pathogenic variants lead to LGMD2Q. (جين PLEC ينتج بروتين البلكتين الضروري للحفاظ على ألياف العضلات؛ أي طفرات مرضية في كلا النسختين تؤدي إلى ضمور العضلات الحزامي 2Q.)
2. Who should consider this PLEC Genetic Test in the UAE?
Any individual with progressive proximal muscle weakness, positive family history, or elevated CK plus myopathic EMG should be offered this. (أي شخص يعاني من ضعف تدريجي في عضلات الحوض والكتف، مع تاريخ عائلي إيجابي، يجب أن يُعرض عليه الفحص.)
3. What does UAE law say about genetic testing in minors for muscular dystrophy?
Under the 2026 Child Data Sovereignty (CDS) Law, predictive genetic testing for healthy minors is prohibited unless a DHA‑accredited genetic counsellor confirms imminent medical benefit – parental consent is mandatory. (بموجب قانون سيادة بيانات الطفل الاتحادي 2026، يُحظر الفحص الجيني التنبؤي للقصر الأصحاء إلا بموافقة من مستشار وراثي معتمد من هيئة الصحة.)
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians